Management of extensive subfoveal haemorrhage secondary to neovascular age-related macular degeneration

Eye

Volumn 23, Issue 6, 2009, Pages 1404-1410

  Sacu, S ^a   Stifter, E ^a   Vecsei Marlovits P V ^a   Michels, S ^b   Schutze C ^a   Prunte C ^a   Schmidt Erfurth, U ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b UNIVERSITY OF ZURICH   (Switzerland)

Author keywords

Avastin; Gas; Lucentis; Recombinant tissue plasminogen activator; Subfoveal haemorrhage

Indexed keywords

ACETAZOLAMIDE; ALTEPLASE; BEVACIZUMAB; DEXAGENTA POS AUGENTROPFEN; DEXAMETHASONE; DORZOLAMIDE PLUS TIMOLOL; GENTAMICIN; RANIBIZUMAB; SULFUR HEXAFLUORIDE; UNCLASSIFIED DRUG;

AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; HUMAN; INTRAOCULAR PRESSURE ABNORMALITY; MONOTHERAPY; NEOVASCULAR AGE RELATED MACULAR DEGENERATION; PILOT STUDY; RETINA; RETINA MACULA AGE RELATED DEGENERATION; RETINA MACULA HEMORRHAGE; RETROSPECTIVE STUDY; THICKNESS; UNSPECIFIED SIDE EFFECT; VISUAL ACUITY; VITRECTOMY;

AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; IMMUNOLOGIC FACTORS; INTRAVITREAL INJECTIONS; MACULAR DEGENERATION; MALE; OUTCOME ASSESSMENT (HEALTH CARE); PILOT PROJECTS; RECOMBINANT PROTEINS; RETINAL HEMORRHAGE; RETROSPECTIVE STUDIES; TISSUE PLASMINOGEN ACTIVATOR; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY;

EID: 67650650973     PISSN: 0950222X     EISSN: 14765454     Source Type: Journal    
DOI: 10.1038/eye.2008.267     Document Type: Article

References (29)

1. Avery R, Fekrat S, Hawkins B, Bressler N. Natural history of subfoveal subretinal hemorrhage in age-related macular degeneration. Retina 1996; 16:183-189.
2. Bennett SR, Folk JC, Blodi CF, Klugman M. Factors prognostic of visual outcome in patients with subretinal hemorrhage. Am J Ophthalmol 1990; 109:33-37.
3. Mozaffarieh M, Heinzl H, Sacu S, Wedrich A. In-patient management and treatment satisfaction after intravitreous plasminogen activator injection. Graefes Arch Clin Exp Ophthalmol 2006; 244:1421-1428.
4. Ibanez HE, Williams DF, Thomas MA, Ruby AJ, Meredith TA, Boniuk I et al. Surgical removal of submacular hemorrhage. A series of 47 consecutive cases. Arch Ophthalmol 1995; 113:62-69.
5. de Juan Jr E, Machemer R. Vitreous surgery for hemorrhagic and fibrous complications of age-related macular degeneration [case report]. Am J Ophthalmol 1988; 105:25-29.
6. Vander JF, Federman JL, Greven C, Slusher MM, Gabel VP. Surgical removal of massive subretinal hemorrhage associated with age-related macular degeneration. Ophthalmology 1991; 98:23-27.
7. Hanscom TA, Diddie KR. Early surgical drainage of macular subretinal hemorrhage. Arch Ophthalmol 1987; 105:1722-1723.
8. Wade EC, Flynn HW, Olsen KR, Blumenkranz MS, Nicholson DH. Subretinal hemorrhage management by pars plana vitrectomy and internal drainage. Arch Ophthalmol 1990; 108:973-978.
9. Haupert CL, McCuen BW, Jaffe GJ, Steuer ER, Cox TA, Toth CA et al. Pars plana vitrectomy, subretinal injection of tissue plasminogen activator, and fluid-gas exchange for displacement of thick submacular hemorrhage in age-related macular degeneration. Am J Ophthalmol 2001; 131:208-215.
10. Schulze SD, Hesse L. Tissue plasminogen activator plus gas injection in patients with subretinal hemorrhage caused by age-related macular degeneration: predictive variables for visual outcome. Graefes Arch Clin Exp Ophthalmol 2002; 240:717-720.
11. Hesse L, Schmidt J, Kroll P. Management of acute submacular hemorrhage using recombinant tissue plasminogen activator and gas. Graefes Arch Clin Exp Ophthalmol 1999; 237:273-277.
12. Hesse L, Kroll P. Successful treatment of acute subretinal hemorrhage in age-related macular degeneration by combined intravitreal injection of recombinant tissue plasminogen activator and gas. Adv Ther 1997; 14:275-280.
13. Spaide RF, Fisher YL. Intravitreal bevacizumab (Avastin) treatment of proliferative diabetic retinopathy complicated by vitreous hemorrhage. Retina 2006; 26:275-278.
14. Soliman W, Lund-Andersen H, Larsen M. Resolution of subretinal haemorrhage and fluid after intravitreal bevacizumab in aggressive peripapillary subretinal neovascularization. Acta Ophthalmologica Scandinavica 2006; 84:707-708.
15. Aiello L, Brucker A, Chang S, Cunningham Jr ET, D'Amico DJ, Flynn Jr HW et al. Evolving guidelines for intravitreous injections. Retina 2004; 24:3-19.
16. Gragoudas ES, Adamis AP, Cunningham ET, Feinsod M, Guyer DR. The Vegf inhibition study in ocular neovascularization clinical trial group. pegaptanib for neovascular age-related macular degeneration. N Engl J Med 2004; 351:2805-2816.
17. Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, et al., MARINA Study Group. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006; 355:1419-1431.
18. Fung AE, Rosenfeld PJ, Reichel E. The International Intravitreal Bevacizumab Safety Survey: using the Internet to assess drug safety worldwide. Br J Ophthalmol 2006; 90:1344-1349.
19. Lewis H. Intraoperative fibrinolysis of submacular hemorrhage with tissue plasminogen activator and surgical drainage. Am J Ophthalmol 1994; 118:559-568.
20. Lim JI, Drews-Botsch C, Sternberg Jr P, Capone Jr A, Aaberg Sr TM. Submacular hemorrhage removal. Ophthalmology 1995; 102:1393-1399.
21. Claes C, Zivojnovic R. Efficacy of tissue plasminogen activator (t-PA) in subretinal hemorrhage removal. Bull Soc Belge Ophtalmol 1996; 261:115-118.
22. Kamei M, Tano Y, Maeno T, Ikuno Y, Mitsuda H, Yuasa T. Surgical removal of submacular hemorrhage using tissue plasminogen activator and perfluorocarbon liquid. Am J Ophthalmol 1996; 121:267-275.
23. Moriarty AP, McAllister IL, Constable IJ. Initial clinical experience with tissue plasminogen activator (tPA) assisted removal of submacular haemorrhage. Eye 1995; 9:582-588.
24. Hattenbach L-O, Brieden M, Koch F, Gümbel H. Intravitreal injection of rt-PA and gas in the management of minor submacular haemorrhages secondary to age-related macular degeneration [Article in German]. Klin Monatsbl Augenheilkd 2002; 219:512-518.
25. Hassan AS, Johnson MW, Schneiderman TE, Regillo CD, Tornambe PE, Poliner LS et al. Management of submacular hemorrhage with intravitreous tissue plasminogen activator injection and pneumatic displacement. Ophthalmology 1999; 106:1900-1907.
26. Glatt H, Machemer R. Experimental subretinal hemorrhage in rabbits. Am J Ophthalmol 1982; 94:762-773.
27. Toth C, Morse L, Hjelmeland L, Landers M. Fibrin directs early retinal damage after experimental subretinal hemorrhage. Arch Ophthalmol 1991; 109:723-729.
28. Stifter E, Michels S, Prager F, Georgopoulos M, Polak K, Hirn C et al. Intravitreal bevacizumab therapy for neovascular age-related macular degeneration with large submacular hemorrhage. Am J Ophthalmol 2007; 144:886-892.
29. Meyer CH, Scholl HP, Eter N, Helb HM, Holz FG. Combined treatment of acute subretinal haemorrhages with intravitreal recombined tissue plasminogen activator, expansile gas and bevacizumab: a retrospective pilot study. Acta Ophthalmol 2008; 86(5):490-494.